Abbisko Cayman Ltd
HKEX:2256

Watchlist Manager
Abbisko Cayman Ltd Logo
Abbisko Cayman Ltd
HKEX:2256
Watchlist
Price: 4.4 HKD 0.23%
Market Cap: 3B HKD
Have any thoughts about
Abbisko Cayman Ltd?
Write Note

Abbisko Cayman Ltd
Effect of Foreign Exchange Rates

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Abbisko Cayman Ltd
Effect of Foreign Exchange Rates Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Effect of Foreign Exchange Rates CAGR 3Y CAGR 5Y CAGR 10Y
Abbisko Cayman Ltd
HKEX:2256
Effect of Foreign Exchange Rates
ÂĄ18.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Effect of Foreign Exchange Rates
ÂĄ44.1m
CAGR 3-Years
N/A
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Effect of Foreign Exchange Rates
ÂĄ18.5m
CAGR 3-Years
N/A
CAGR 5-Years
47%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Effect of Foreign Exchange Rates
ÂĄ7.6m
CAGR 3-Years
N/A
CAGR 5-Years
50%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Effect of Foreign Exchange Rates
-ÂĄ2.8m
CAGR 3-Years
24%
CAGR 5-Years
N/A
CAGR 10-Years
-25%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Effect of Foreign Exchange Rates
-ÂĄ2.1m
CAGR 3-Years
21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Abbisko Cayman Ltd
Glance View

Market Cap
3.1B HKD
Industry
Biotechnology

Abbisko Cayman Ltd. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of drugs and small molecule oncology therapies. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-10-13. The firm is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The firm owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Company’s products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).

Intrinsic Value
3.2 HKD
Overvaluation 27%
Intrinsic Value
Price

See Also

What is Abbisko Cayman Ltd's Effect of Foreign Exchange Rates?
Effect of Foreign Exchange Rates
18.6m CNY

Based on the financial report for Dec 31, 2023, Abbisko Cayman Ltd's Effect of Foreign Exchange Rates amounts to 18.6m CNY.

What is Abbisko Cayman Ltd's Effect of Foreign Exchange Rates growth rate?
Effect of Foreign Exchange Rates CAGR 1Y
-88%

Over the last year, the Effect of Foreign Exchange Rates growth was -88%.

Back to Top